Selective N-Type Calcium Channel Blockers for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current calcium channel blockers lack selectivity for N-type channels over L-type channels, leading to potential hypotensive effects and a need for antagonists that specifically target N-type calcium channels to manage pain and neuroprotection without adverse cardiovascular effects.
Innovation Solution
Development of novel piperidinyl and hexahydroazepinyl compounds that act as selective N-type calcium channel blockers, administered as pharmaceutical compositions to treat various disorders including pain, stroke, and neurodegenerative diseases, while avoiding the hypotensive effects associated with L-type channel inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective calcium channel blockers are used to achieve pain relief and neuroprotection, then therapeutic efficacy is improved, but hypotensive effects worsen
Solution Approach 1:
The patent applies local quality by designing calcium channel blockers with specific molecular structures (Formula I compounds with defined substituents R1-R16) that confer selective affinity for N-type channels over L-type channels. This molecular-level differentiation allows the drug to exert therapeutic effects at N-type channels while minimizing effects at L-type channels, thereby avoiding hypotension.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying molecular parameters (substituents at specific positions, heterocyclic ring sizes, chain lengths) to optimize the balance between N-type channel blocking activity and L-type channel activity. This structure-activity relationship optimization enables tuning of the drug's selective profile to achieve therapeutic efficacy without hypotensive side effects.
2Reliability
If L-type calcium channels are inhibited to achieve neuroprotection, then neuroprotective effects are improved, but blood pressure control worsens
Solution Approach 1:
The patent applies segmentation by differentiating between N-type and L-type calcium channels and designing selective blockers that target only the N-type subset. This segmentation approach allows neuroprotection to be achieved through N-type channel blocking in the spinal cord without inadvertently blocking L-type channels in the heart and blood vessels, thus avoiding blood pressure drops.
Solution Approach 2:
The patent uses an intermediary approach by introducing selectively active compounds as mediators between the therapeutic goal (neuroprotection) and the potential harmful effect (hypotension). The Formula I compounds act as intermediary substances that selectively interact with N-type channels to provide neuroprotection while having minimal interaction with L-type channels, thereby preventing blood pressure reduction.
3Object-affected harmful factors
If selective N-type calcium channel blockers are developed to avoid hypotension, then safety profile is improved, but drug development complexity worsens
Solution Approach 1:
The patent applies universality by designing a unified structural framework (Formula I) that generates multiple compounds with similar selective properties. This master structure with variable substituents allows systematic exploration of N-type selective blockers without requiring entirely different molecular paradigms, thereby managing development complexity through a cohesive design strategy.
Solution Approach 2:
The patent manages development complexity by using parameter changes within a systematic framework. By varying specific parameters (substituents at defined positions, heterocyclic configurations) within the Formula I scaffold, multiple selective N-type blockers can be generated efficiently, reducing the need to explore entirely new molecular spaces and thus managing the complexity of drug discovery.
Data Source
AI summary
The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.